Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Extension Clinical Trial to Demonstrate Efficacy and Safety of Liposomal Cyclosprine A Via the PARI Investigational eFlow® Device and SoC in Treating Bronchiolitis Obliterans in Patients Post Single or Double Lung Transplant

NCT04039347 is registered in ClinicalTrials.gov with Zambon SpA as lead sponsor.

NCT NCT04039347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04039347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Extension Clinical Trial to Demonstrate Efficacy and Safety of Liposomal Cyclosprine A Via the PARI Investigational eFlow® Device and SoC in Treating Bronchiolitis Obliterans in Patients Post Single or Double Lung Transplant
Lead sponsor
Zambon SpA
Phase
Phase 3
Overall status
Terminated
Start date
March 12, 2020
Completion date
February 25, 2026
Enrollment
164 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiolitis obliterans, bronchiolitis obliterans syndrome, obliterative bronchiolitis